J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

How does the US stock market stack up against its UK counterpart and how does their recent performance compare?

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

GSK (GSK) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good ...

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...